In 2024, the FDA approved biosimilar versions of Eylea, including the brand names Ahzantive, Enzeevu, Pavblu, Opuviz, and Yesafili. Anti-VEGF Treatments in the Pipeline In addition to injections, ...

approved Eylea biosimilars. These include the following: Yesafili (aflibercept-jbvf) Opuviz (aflibercept-yszy) Pavblu (aflibercept-ayyh) Ahzantive (aflibercept-mrbb) Enzeevu (aflibercept-abzv) ...

This case involves an appeal from Regeneron Pharmaceuticals, Inc.’s (Regeneron) efforts to prevent defendants from marketing biosimilar versions ...

After consecutive setbacks at the FDA, Regeneron's string of recent troubles with its Eylea franchise is continuing to pull down the drugmaker. Over the first three months of 2025, Regeneron's ...

which competes with Eylea HD, and Pabvlu, a biosimilar version of the original dose Eylea. Moreover, in April 2025, Regeneron's US supplementary application for Eylea HD's prefilled syringe was ...

Meanwhile, its high-dose version, known as Eylea HD, brought in $453M, with over a twofold rise from the prior year period. Meanwhile, REGN’s asthma drug Dupixent, marketed with Sanofi (SNY ...

An EMA committee has issued a positive opinion for a label extension that would allow six-month injection intervals for Eylea ...

Regeneron Pharmaceuticals stock was among the biggest S&P 500 and Nasdaq decliners Tuesday after the biotech firm reported first-quarter sales—especially those of its key Eylea eye disease drug ...

Selarsdi, a human interleukin-12 and -23 antagonist, is currently indicated for: The FDA originally approved Selarsdi as a biosimilar for plaque psoriasis and psoriatic arthritis in April 2024 ...

The Eylea franchise has several moving parts, including competitive pressure from Amgen's biosimilar Pavblu, a complete response letter in the US for Eylea HD's prefilled syringe, and a funding ...

Bayer said it needed expert input on high-dose Eylea to inform the launch, particularly at a time when the market was evolving quickly, as Lucentis biosimilars and Roche’s competing Vabysmo ...